With federal funding, Gemstone Biotherapeutics is eying development of the next generation of its wound-healing technology.

The Federal Hill startup is developing treatments that enable skin regeneration without scars.

WellDoc®, a leading digital health company revolutionizing chronic disease management to help transform lives through the use of its digital therapeutics, today announced results from an innovative economic analysis that demonstrated the potential for significant healthcare cost savings with the use of BlueStar®. BlueStar is powered by WellDoc and is a 510K-cleared digital therapeutic designed to coach adults with type 2 diabetes.

CosmosID a bioinformatics provider and NGS service laboratory announced that the company’s cloud-based bioinformatics platform for microbiome analysis has received the highest score in the strain-level microbial profiling category of the Mosaic Community Challenge and for strain-level microbial identification in the precisionFDA Pathogen Detection Challenge.

gel-e Inc., announces the 510(k) clearance of gel-e FLEX by the U.S. Food and Drug Administration (FDA) for the over-the-counter (OTC) use of its first flowable hemostat.

This new clearance expands the Company's label that now includes the use of gels and bandages in the local management of bleeding, such as lacerations and minor bleeding. These products are specifically designed to create rapid hemostasis through easy-to-use applications for professional healthcare providers, parents, coaches, adult caregivers and even patients themselves. gel-e FLEX also complements the Company's already FDA cleared vascular closure device, Vascular gel-e®, as it can be worn home by patients to manage any residual bleeding from an out-patient diagnostic or interventional procedure, see http://www.gel-e.co/products.html.

Though we’re nowhere near machines taking over, artificial intelligence has a plethora of applications in healthcare. The oncology space is no exception.

The intersection of artificial intelligence and cancer care is up for discussion at the forthcoming MedCity CONVERGE conference in Philadelphia on July 11-12.

Leslie Weber was inducted in June as chair of the board of directors of the Montgomery County Chamber of Commerce. Weber is director of the Johns Hopkins University Montgomery County Campus and director of government and community affairs for Johns Hopkins in Montgomery County. She long has been involved with the Chamber: She has held leadership positions on the board and received the Chairman’s Award in 2016.

The city has begun testing its hypothesis that real estate costs and other hurdles stood in the way of a booming life science sector by supporting three biotech incubators.

Two of the incubators, which offer young companies an affordable workspace, lab equipment and networking opportunities, have started welcoming tenants. But data on the strategy’s success has been sparse.

The Maryland Technology Enterprise Institute (Mtech) at the University of Maryland, College Park seeks an organized, energetic person to assist with operational functions and related activities for the Entrepreneurship and Innovation Program in the Honors College.

This nationally award-winning program helps to develop the entrepreneurial mindsets, skill sets and resources for first and second-year students.

The position-holder would provide coordination and support for

program operations and administration courses and curriculum student activities and engagement marketing and recruiting development and grants

Johns Hopkins University is again the top NIH grant recipient in Greater Baltimore in 2017, with a total grant value of $651.8 million last year.

The university also led all U.S. universities in research and development expenditures for the 38th consecutive year in fiscal year 2016, spending $2.4 billion on various research projects.

Two Rockville employers are among the top workplaces in the region, according to The Washington Post's newest ranking.

There is limited data available on Health Tech investing in general and even less related to early stage investing in the sector. IPHA set out to fill that gap by analyzing quarterly health tech investing data between 2010 through Q1 2018. We track both total investment dollars and deals completed over the period with additional analysis of the five quarters leading up to March 31, 2018. There is an unmistakeable trend reversal that started in Q1 2017 that is significant for both health tech entrepreneurs and investors.

Women and men almost equally shared all positions in the life sciences world, but women are not advancing in their biopharma careers at the same pace as men, according to a recent report by the Massachusetts Biotechnology Council and recruiting firm Liftstream. The wide gender gap higher up, though improved in recent years, persists: Women only hold a quarter of all C-suite level jobs, and less than 15% joined the board of directors.

Lupin has announced that it has partnered with Mylan to commercialize Enbrel (Etanercept) biosimilar. Under the terms of the agreement, Lupin will receive an up-front payment of $15mn and potential commercial milestones together with an equal share in net profits of the product. Mylan will commercialize Lupin's Etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.

Venture investors poured more than $1 billion into agtech last year, and we are on pace to match or exceed that this year. The convergence of AI, cloud computing, big data and gene editing, with applications from soil to plants, foods to medicines, farm to table are driving investments. Discerning startups and investors will capitalize from the market’s current, numerous opportunities.

Changes are afoot at GE. The company will separate GE Healthcare into a standalone company.

Kieran Murphy, the president and CEO of GE Healthcare, will continue at the helm of the business, which offers medical imaging, biomanufacturing and data analytics capabilities, among other services.

Carisma Therapeutics, formerly Carma Therapeutics, is working on a new onco-immunotherapy approach for treating cancer patients with solid tumors.

Without fanfare, the University of Pennsylvania has agreed to invest up to $50 million over the next three years in at least 10 biotech companies, the Inquirer has learned.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $12 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Senseonics.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.

Hospitals in D.C. and Baltimore rank among the best in the nation, according to a new list released by U.S. News & World Report.

Overall, Children’s National Medical Center in D.C. ranked No. 5 and John’s Hopkins Children’s Center in Baltimore ranked No. 8 on the “honor roll,” which lists the best-performing children’s hospitals across 10 pediatric specialties including neonatal care, neurology, cancer and cardiology.

Joel Grimwood needed a new heart, but a chronic bacterial infection lurking within his implanted ventricle assist device made getting one impossible. Five transplant centers declined his case due to his persistent infection. Then Grimwood came to UC San Diego Health, where doctors treated the infection with an experimental bacteriophage therapy – viruses that eat bacteria. The infection cleared and Grimwood got his new heart.

The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to fight multidrug-resistant bacteria. The initial focus will be on treating chronic infections associated with cystic fibrosis, organ transplantation and implantable hardware. The center hopes to start clinical trials by year end.

What started with a wife’s stubborn refusal to give up on her husband who lay dying of a superbug infection has become a whole new research initiative at UC San Diego.

One piece of good news can make all the difference. In the fight against antibiotic-resistant infections, a decades-old approach based on bacteria-slaying viruses called phages has been sidelined by technical hurdles, dogged by regulatory confusion, and largely ignored by drug developers in the West. But 2 years ago, researchers at the University of California, San Diego (UCSD), used phages to knock out an infection that nearly killed a colleague. Propelled by that success and a handful of others since, UCSD is now launching a clinical center to refine phage treatments and help companies bring them to market.

A new medical research center in San Diego is embracing an innovative way to treat antibiotic resistant infections called bacteriophage therapy—phage therapy for short—which uses viruses as weapons against hard-to-treat infections.

When her husband was dying of a drug-resistant infection, Steffanie Strathdee had a last-ditch idea. They could try treating him with a virus that would kill the bacteria colonizing his insides. The method, called phage therapy, was popular in former Soviet republics, but had mostly been abandoned in the U.S. Researchers had to hunt for the right virus in Texas pigsties and sewage treatment plants.

The Greater Washington Partnership, an alliance of local CEOs, is launching a formal collaboration program with a swath of regional universities — part of an effort to spur the development of more tech-focused workers.

United Therapeutics CEO Martine Rothblatt may not sound like a familiar name to an average person, but in the healthcare industry, she is a living legend. Rothblatt was the second-highest paid female CEO in the U.S. in 2017—and the 19th highest paid overall. (She was the highest-paid female CEO in the U.S. in 2013.)

We’re hearing more and more about precision medicine and how it can positively impact medicine. But what is preventing it from reaching its full potential, and how can everyone from hospitals to startups help scale it?

Silence Therapeutics has appointed Dave Lemus to its Board as non-executive director and Richard Jenkins as head of clinical development. Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. He is currently executive vice chair, chief operating officer and CFO of Proteros biostructures. He also currently serves as a non-executive board member of BioHealth Innovation, Sorrento Therapeutics, and the MIT Club of Washington DC.

The second annual Iowa AgriTech Accelerator has chosen five start-up companies to participate in its 2018 program. These innovators will spend 100 days in Des Moines, Iowa, working with mentors in the AgTech industry who will help them with their business plan and making contacts that could help with funding, distribution, etc. They will also receive $40,000 in funding from the program’s sponsors.

TEDCO plans to provide funding and business-building programming to entrepreneurs from groups who are often overlooked by investors through a new fund that will begin this fall.

From cofounding Sirius Satellite Radio to launching a biotech company to find a cure for her daughter’s illness, Martine Rothblatt has had so much career success that any one of her accomplishments would be a crowning achievement for another entrepreneur. “I always try to convert a moonshot into an earthshot,” Rothblatt told hundreds at the Forbes Women’s Summit on Tuesday.

Marriott International, the world’s largest hotel chain, on Thursday broke ground on the $600 million project to build a headquarters in downtown Bethesda.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., Ltd. for the manufacturing of entecavir and cilostazol. Yiling Wanzhou International Pharmaceutical Co., Ltd. is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd. The contracted manufacturing facilities have been inspected by both the U.S. Food and Drug Administration (FDA) and China FDA (CFDA) and operate to strict International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Manufacturing Practice (GMP) standards, which will enable CASI to eventually sell both entecavir and cilostazol in the U.S., China and worldwide markets. Entecavir and cilostazol are part of the 29 abbreviated new drug applications (ANDAs) that CASI acquired from Sandoz in January 2018.